Thus, to successfully treat resistant CML, alternative strategies are highly desirable to target BCR/ABL expression and its gene regulators with approaches distinct from those employed by conventional tyrosine kinase inhibitors. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.